GA
PHAT icon

Greenspring Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

Greenspring Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-415,277
Closed -$14.1M – 6
2021
Q2 		$14.1M Buy
415,277
+54,338
+15% +$1.95M 0.95% 6
2021
Q1 		$13.6M Hold
360,939
– – 10.78% 4
2020
Q4 		$12M Buy
360,939
+130,212
+56% +$5.28M 15.57% 2
2020
Q3 		$8.46M Sell
230,727
-150,342
-39% -$5.21M 13.17% 4
2020
Q2 		$12.5M Buy
381,069
+20,130
+6% +$773K 7.7% 5
2020
Q1 		$9.32M Hold
360,939
– – 3.86% 6
2019
Q4 		$11.2M Buy
+360,939
New +$9.07M 2.96% 7

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Greenspring Associates's PHAT Position: Q3 2021 in Review

Greenspring Associates sold out of Phathom Pharmaceuticals (PHAT) in Q3 2021, closing a stake of 415,277 shares — an estimated $14.1M sold.

Greenspring Associates first reported a position in PHAT in Q4 2019 and held it in 7 quarters. The position peaked at $14.1M in Q2 2021. 84 funds tracked by Wall St. Rank hold PHAT as of Q3 2021.

  • Greenspring Associates reported no remaining Phathom Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Greenspring Associates sold 415,277 Phathom Pharmaceuticals shares in Q3 2021, an estimated $14.1M.
  • Greenspring Associates first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Greenspring Associates's Phathom Pharmaceuticals position peaked at $14.1M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2021.

Based on Greenspring Associates's 13F filing for Q3 2021.